Conservative Treatment of Retinoblastoma

Jc, Hernandez; Lw, Brady; Shields, C.L.; Shields, Jennie; DePotter, Patrick

doi:10.1097/00000421-199310000-00005

Cited by 28 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Eyes containing tumors that display clinical features threatening to extend beyond the globe may be surgically removed (enucleation) and histologically assessed to determine risk of metastasis. Eye salvage may be attempted on less severely affected eyes (Dimaras et al, ; National Retinoblastoma Strategy, ), with focal therapy (laser, cryotherapy) (Hamel, Heon, Gallie, & Budning, ), brachytherapy (Hernandez, Brady, Shields, Shields, & DePotter, ), and/or chemotherapy. Chemotherapy may be systemic, usually with a cocktail of vincristine, etoposide, and carboplatin (Chan et al, ; Gallie et al, ); intra‐arterial (Yousef et al, ); and/or intravitreal (Munier, Gaillard, et al, ; Munier, Soliman, et al, ).…”

Section: Retinoblastoma Overviewmentioning

confidence: 99%

Retinoblastoma, the visible CNS tumor: A review

Dimaras

Corson

2018

J of Neuroscience Research

141

112

View full text Add to dashboard Cite

The pediatric ocular cancer retinoblastoma is the only central nervous system (CNS) tumor readily observed without specialized equipment: it can be seen by, and in, the naked eye. This accessibility enables unique imaging modalities. Here, we review this cancer for a neuroscience audience, highlighting these clinical and research imaging options, including fundus imaging, optical coherence tomography, ultrasound, and magnetic resonance imaging. We also discuss the subtype of retinoblastoma driven by the MYCN oncogene more commonly associated with neuroblastoma, and consider trilateral retinoblastoma, in which an intracranial tumor arises along with ocular tumors in patients with germline RB1 gene mutations. Retinoblastoma research and clinical care can offer insights applicable to CNS malignancies, and also benefit from approaches developed elsewhere in the CNS.

show abstract

Section: Retinoblastoma Overviewmentioning

confidence: 99%

Retinoblastoma, the visible CNS tumor: A review

Dimaras

Corson

2018

J of Neuroscience Research

141

112

View full text Add to dashboard Cite

show abstract

“…The indications include solitary tumors located anterior to the equator upto the ora serrata, primary unilateral retinoblastoma of size <16 mm in base, and <8 mm in thickness, and recurrent or residual tumors after primary chemotherapy or failed EBRT. [ 25 26 27 28 ] Relative contraindications include larger tumors and those involving the macula. Radioisotopes such as Iodine (I 125 ) and Ruthenium (Ru 106 ) are the most commonly used isotopes.…”

Section: Treatment Modalities: Which When How?mentioning

confidence: 99%

“…Side effects of radiation therapy include dryness of the eye, irritation, madarosis, cataract, scleral necrosis, radiation retinopathy or papillopathy, optic neuropathy, and strabismus. [ 25 26 27 28 ] Second malignancies do not appear to be associated with this type of local therapy. In one study on the role of plaque brachytherapy in retinoblastoma, Shields et al .…”

Section: Treatment Modalities: Which When How?mentioning

confidence: 99%

Conservative treatment modalities in retinoblastoma

Chawla

Jain

Azad

2013

Indian J Ophthalmol

View full text Add to dashboard Cite

Retinoblastoma is the most common primary intraocular malignancy of childhood. A potentially curable cancer, its treatment has improved significantly over the last few decades. The purpose of this article is to review the literature on various conservative treatment modalities available for the treatment of retinoblastoma and their effectiveness, when used alone or in combination. Pubmed, Medline, Embase, and the Cochrane library were searched through 2012 for published peer reviewed data on conservative treatment modalities for retinoblastoma. Various studies show that while enucleation remains the standard of care for advanced intraocular tumors, conservative modalities that can result in globe salvage and preservation of useful vision are being increasingly employed. Such modalities include systemic chemotherapy, focal consolidation with transpupillary thermotherapy, laser photocoagulation and cryotherapy, plaque brachytherapy, and delivery of local chemotherapy using subconjunctival, sub-tenon, or intra-arterial routes. When used alone or in combination, these treatment modalities can help in avoidance of external beam radiotherapy or enucleation, thus reducing the potential for long-term side effects, while salvaging useful vision. Radioactive plaque brachytherapy has an established role in selected patients with intraocular retinoblastoma. Local injections of chemotherapeutic agents via the sub-tenon or sub-conjunctival route have been used with varying degrees of success, usually as an adjunct to systemic chemotherapy. Intra-arterial ophthalmic artery delivery of melphalan has shown promising results. It is important to recognize that today, several treatment options are available that can obviate the need for enucleation, and cure the cancer with preservation of functional vision. A thorough knowledge and understanding of these conservative treatment modalities is essential for appropriate management.

show abstract

What Is the Evidence Supporting Chemotherapy for Intraocular Retinoblastoma?

Hernandez¹

1997

Arch Ophthalmol

View full text Add to dashboard Cite

Conservative Treatment of Retinoblastoma

Cited by 28 publications

References 0 publications

Retinoblastoma, the visible CNS tumor: A review

Retinoblastoma, the visible CNS tumor: A review

Conservative treatment modalities in retinoblastoma

What Is the Evidence Supporting Chemotherapy for Intraocular Retinoblastoma?

Contact Info

Product

Resources

About